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Introduction 
 
 
 
During the last years, treatment strategies in oncology have undergone considerable 
improvements due to a better understanding of tumour biology. In particular, a new branch 
of pathology, the so-called predictive molecular pathology, aims to define a better 
therapeutic strategy applying the basic principle "the most appropriate drug for any single 
patient". Thus, tumour tissue samples are analysed in molecular pathological laboratories to 
detect actionable genomic alterations. Thus, in each laboratory a wide range of different 
techniques is developed and validated, also taking care to assess continuously the quality of 
testing. 
Technology is advancing at a rapid pace and fully automated platform are emerging 
for rapid molecular testing. In particular the Idylla™ (Biocartis NV, Mechelen, Belgium) 
system is a fascinating technology. The system relies on a molecular diagnostic device for 
detection of genetic mutations based on automated quantitative allele-specific RT-PCR.1-3 
The apparatus features a sample preparation module integrated with a combined PCR 
thermocycling and fluorescence detection module connected to the computer-console. All 
consumables required to perform sample preparation and RT-PCR detection are provided in 
disposable cartridges that are loaded onto the Idylla™ system to enable the simultaneous 
detection of up to 30 molecular targets from a variety of solid and liquid sample types, 
including DNA preparations from routine cytological specimens. Through microfluidic 
channels in the cartridge, nucleic acids are transported into five separate PCR chambers, 
which contain predeposited PCR reagents in dried form (i.e., primers, probes, enzymes). 
Closing of the cartridge after inserting the sample avoids cross contamination. The Idylla™ 
method is very simple and rapid, with a time around testing approximatively two hours. 
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There are many types of cartridge on the market developed for many gene mutational test, 
already being widely adopted on histological materials. 
In routine practice, molecular testing in predictive pathology laboratories is often 
performed on cytological, rather than on histological samples. Fine Needle Aspiration (FNA) 
samples are obtained by minimally invasive procedures and represent the best option in 
patients with advanced metastatic diseases to guide targeted therapy. The aim of this 
Doctorate Thesis is therefore, to validate the Idylla™ technology on cytological samples of a 
number of different neoplasms such as lung, colon and pancreatic cancers. Briefly, this 
Thesis will focus on the validation two different Idylla™ molecular assays on cytological 
samples. Cytology is versatile approach to the diagnostic evaluation of both morphology and 
genomic alterations of neoplastic cells. In fact, different modalities of fixation, 
cytopreparation and staining enable cytology to address a large number of different 
applications. Although versatility is a remarkable feature of cytology, the variability of 
different specimens types may be an issue when validating a novel molecular approach. In 
this Thesis, special care what taken to validate both EGFR and KRAS Idylla™ assay on a large 
number of different cytological sample types, including direct smears, cytospins, liquid based 
cytology preparations, and cell blocks. A constant effort was spent to provide an effective 
and well addressed research aimed to address a relevant and important issue, the validation 
of the Idylla™ assays on routine cytological samples. 
The first chapter will focus on lung cancer predictive testing. Recent guidelines from 
the College of American Pathologists (CAP), International Association for the Study of Lung 
Cancer (IASLC) and the Association for Molecular Pathology (AMP) recommend epidermal 
growth factor (EGFR) testing in patients with lung adenocarcinoma, regardless of sex, race, 
smoking history, histological grade or other clinical risk factors.4 If EGFR demonstrates an 
activating (sensitizing) mutation, the first-generation tyrosine kinase inhibitors (TKI) Gefitinib 
(Iressa®, AstraZeneca, London, UK) and Erlotinib (Tarceva®, F. Hoffmann-La Roche, Basel, 
Switzerland), or the second-generation TKI Afatinib (Giotrif®, Boehringer Ingelheim, 
Ingelheim, Germany) should be given as first-line therapy. To date, EGFR testing is often 
centralized in large laboratories, with longer testing times. In this scenario, Idylla™ may 
represent a viable option to widespread EGFR testing even in less experienced and equipped 
laboratories. As it is detailed in chapter 1, this Thesis provides a large body of evidences 
demonstrating that Idylla™ testing can reliably be applied to Non Small Cell Lung Cancer 
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(NSCLC) cytological samples, with a short time around testing and high cost-effective results. 
In the second chapter of this Thesis, we aimed to validate on cytological samples the KRAS 
Idylla™ assay. Previous studies showed that the Idylla™ technology is suitable for paraffin 
histological blocks, which is relevant since KRAS mutations have a remarkable clinical 
significance in a large number of human neoplasms. In particular, KRAS testing can provide 
both diagnostic and predictive information. As an example, the diagnosis of pancreatic 
cancer may be aided by the demonstration of an oncogenic KRAS mutation to differentiate 
between mucinous from non mucinous lesions.5 Since cytological sample are often used to 
diagnose pancreatic masses, investigation focusing on the application of novel technologies 
on pancreatic cytology is relevant. In this Thesis, we demonstrated that KRAS Idylla™ assay 
on may be well performed with useful results on pancreatic FNA samples. 
Besides its diagnostic relevance, the detection of KRAS mutations have also 
remarkable predictive significance. In particular, KRAS testing is mandatory to select colon 
cancer patients for the therapy with Monoclonal Antibody (MoAbs) against EGFR, such as 
Cetuximab or Panitumumab. In the routine clinical setting, KRAS testing is usually performed 
on resected primary histological tumor samples of colon cancer, but the cytological sampling 
of the metastatic sites can be useful when there is complete response to neoadjuvant in 
patients with rectal cancer6 and to serially monitor for the emergence of mutant treatment 
resistant clones.7 8 In this setting, KRAS testing on cytological samples is an useful 
opportunity and, in this Thesis, Idylla KRAS testing has been validated also for this 
application, as detailed in chapter 2. 
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Chapter 1 
 
 
 
1.1 Idylla EGFR testing 
 
 
 
The Idylla EGFR Mutation Assay is a single-use cartridge-based test. Via microfluidic 
channels in the cartridge nucleic acids are transported into five separate PCR chambers, 
which contain predeposited PCR reagents in dried form (ie, primers, probes, enzymes) 
designed for the qualitative detection of 18 types of genetic changes for which 53 different 
mutations have been validated. These include three different point mutations: p.G719S (c. 
G2155A), p.G719C (c. G2155T), p.G719A (c.G2156C) in exon 18; six different families of 
deletions ranging from 9 to 24 bp in exon 19; five different insertions (p.InsASV9, 
p.InsASV11, p.InsSVD, p.InsG, p.InsH) and two point mutations p.S768I (c.G2303T) and 
p.T790M (c.C2369T) in exon 20 and two point mutations p.L858R (c.T2573G) and p.L861Q 
(c.T2582A) in exon 21. Detection of these specific targets is performed using fluorescently 
labelled probes. The analytic time required to perform the results is approximately 2.5 
hours, with a hands-on time of less than 2 min. 
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1.2 Idylla EGFR Mutation Assay on lung cancer cytological 
specimens 
 
 
 
Testing for Epidermal Growth Factor Receptor (EGFR) mutations is part of the current 
standard of care in advanced non-small cell lung cancer.4 The recent guidelines from the 
College of American Pathologists (CAP), International Association for the Study of Lung 
Cancer (IASLC) and the Association for Molecular Pathology (AMP) recommend EGFR testing 
in patients with lung adenocarcinoma, regardless of sex, race, smoking history, histological 
grade or other clinical risk factors.4 Cytological samples are suitable for EGFR testing, which  
is crucial, since the large majority of patients present in advanced disease stages.4 9 
In patients with acute deterioration, EGFR testing results should be available as soon 
as possible, as administration of EGFR antagonists as second-line agents is less efficient than 
their use in first-line therapy.4 As a general recommendation, tumour specimens should be 
sent to testing laboratories within three working days of receiving oncologist’s requests.4 
However, in a previous survey, we showed the period of time between test request and 
delivery of the sample is in routine practice nearly double the recommended time.10 
Laboratories may use any validated EGFR testing method that is able to detect mutations in 
cytological specimens with as little as 10% tumour cells.4 As a matter of the fact, the 
competence needed to validate molecular diagnostic assays is beyond most cytopathology 
laboratories and, even if there was expertise, a larger number of cases is required to run in- 
house testing cost-effectively.11 Therefore, the current practice is often external centralised 
testing. Unfortunately, this is fraught with a higher rate of inadequate samples than in-house 
testing;12 in fact, the primary cytopathologist is often reluctant ‘to sacrifice’ the morphology 
of malignant cells for DNA extraction, and the smear sent to centralised laboratories is often 
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paucicellular.13 Thus, ideally, EGFR testing should be carried out in the same centre where 
the patient is diagnosed. 
To this end, automated allele-specific real-time PCR (RT-PCR) technology is advancing 
at rapid pace. In particular, the fully automated molecular diagnostics system Idylla™ 
(Biocartis, Mechelen, Belgium) is a fascinating technology.1-3 Sample preparation is combined 
with PCR thermocycling and fluorescence detection of target sequences. Without need in 
highly skilled staff, within approximately 90 min, the European Community (CE)-in vitro 
diagnostic use (IVD) marked Idylla™ mutational tests can genotype V-Raf murine sarcoma 
viral oncogene homolog B (BRAF) and Kirsten rat sarcoma viral oncogene homolog (KRAS) 
with 1% detection limit.1-3 More recently, Biocartis developed an Idylla EGFR test prototype. 
Although, the Idylla™ tests were designed for use with formalin-fixed paraffin-embedded 
(FFPE) sections, the Idylla™ system can also process DNA preparations from cytological 
samples, as previously shown.14 The aim of the present study was to assess the Idylla™ EGFR 
test performance on lung cancer cytological specimens. 
 
 
 
 
 
1.2.1 Material and Methods 
 
 
 
Study design 
 
Study design is graphically shown in figure 1. Preliminarily, the Idylla EGFR Mutation 
Assay analytical sensitivity was assessed on DNA derived from cell lines. Then, Idylla EGFR 
Mutation Assay was carried out on DNA preparations previously extracted from routine 
cytological samples (n=76) quantified (ng/µL) and tested for clinical reporting by in-house 
PCR-based methods (fragment length and TaqMan assays) as previously described.15 In cases 
of discrepancies, next generation sequencing was used as an orthogonal technique, 
following our previously validated protocol.16 In 17 cases, an additional direct smear was 
available and Idylla EGFR Mutation Test was also carried out directly on cytological material 
exploiting the whole Idylla™ system workflow, as explained below. 
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Figure 1. Study design: Idylla EGFR Mutation Assay was carried out on DNA preparations previously extracted 
from routine cytological samples (n=76) and compared with in-house validated PCR-based methods (fragment 
length and TaqMan assays), In 17 cases, an additional direct smear was available and Idylla EGFR Mutation Test 
was also carried out directly on cytological material exploiting the whole Idylla™ system workflow. NSCLC, non- 
small cell lung cancer. 
 
 
 
Analytical sensitivity assessment 
 
The limit of detection of the Idylla EGFR prototype assay was assessed by cell line 
dilution studies. The mutated PC9 (harbouring EGFR p.E746-A750del) and H1975 (carrying 
L858R point mutation) and the A549 (EGFR wt) cell lines were serially mixed at dilutions of 
25%, 10% and 1%. 
 
 
Sample series 
 
We retrospectively selected from our archive 32 patient DNA samples by the 
following criteria: (1) the presence of EGFR exon 19 deletion or exon 21 L858R mutation 
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assessed by our laboratory validated assay (our laboratory is registered in the Italian Society 
of Pathology EGFR external quality control scheme, http://www.egfrquality.it) and (2) the 
availability of a sufficient (10 ng) amount of stored genomic DNA. Overall, 25 cases 
harboured an exon 19 deletion, whereas 7 cases carried the L858R point mutation. To 
ensure specificity of the Idylla EGFR prototype assay, a total of 44 additional EGFR wild-type 
DNA samples extracted from routine cytological specimens were selected. Overall, a total of 
65 cases had ≥20% of neoplastic cells, whereas 11 cases had <20% of cancer cells (table 1). 
 
 
 
 
Case % Neoplastic cells DNA (ng/µL) Reference method Idylla 
1 80 60 WT WT 
2 60 60 L858R L858R 
3 40 60 WT WT 
4 50 7.15 DEL19 DEL15 
5 20 6.9 DEL19 DEL15 
6 70 60 WT WT 
7 30 4.94 DEL19 DEL18/21b/24 
8 10 1.75 WT WT 
9 80 60 WT WT 
10 10 6.56 WT WT 
11 50 5.69 WT WT 
12 40 16.2 L858R L858R 
13 30 2.3 WT WT 
14 15 12.9 WT WT 
15 25 6.33 DEL19 DEL15 
16 50 16 WT WT 
17 80 8.8 WT WT 
18 25 5.71 WT WT 
19 40 16.9 DEL19 DEL15 
20 5 26.3 WT WT 
21 60 11.3 DEL19 DEL15 
22 25 4.79 WT WT 
23 25 4.96 WT WT 
24 23 21.2 WT WT 
25 60 26.1 L858R L858R 
26 50 8.3 DEL19 DEL18/21b/24 
27 30 7.05 WT WT 
28 50 1.99 WT WT 
29 25 5.86 WT WT 
30 25 0.5 WT INVALID 
31 50 15.3 DEL19 DEL15 
32 30 10.9 WT G719A 
33 50 16.8 WT WT 
34 5 3.5 WT DEL15 
35 50 5.21 DEL19 DEL9/21 a 
36 50 6.14 WT WT 
37 60 13.7 WT WT 
38 25 3.71 WT WT 
39 25 1.58 L858R L858R 
40 10 4.08 WT DEL15 
Continued 
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Table 1 Continued 
Case % Neoplastic cells DNA (ng/µL) Reference method Idylla 
40 10 4.08 WT DEL15 
41 30 8.61 WT WT 
42 20 7 WT WT 
43 50 4.57 WT WT 
44 5 14.7 WT WT 
45 5 0.28 WT WT 
46 20 1.21 WT WT 
47 20 2.65 WT WT 
48 50 3 DEL19 DEL15 
49 70 6.5 DEL19 DEL15 
50 25 9 L858R L858R 
51 50 5.19 DEL19 DEL15 
52 50 10 DEL19 DEL15 
53 70 5.7 DEL19 DEL9/21 a 
54 30 2.6 DEL19 DEL12 
55 30 2.7 DEL19 DEL15 
56 50 0.2 L858R L858R 
57 30 5.2 DEL19 DEL15 
58 5 1.21 DEL19 DEL15 
59 20 1.65 WT WT 
60 60 9.07 WT INVALID 
61 50 36.4 WT WT 
62 30 2.87 WT G719C 
63 30 1.29 DEL19 DEL15 
64 5 3.02 DEL19 DEL15 
65 50 20.8 DEL19 DEL15 
66 40 22.4 L858R L858R 
67 50 2.63 DEL19 DEL9/21 a 
68 20 5 DEL19 DEL9/21 a 
69 20 60 WT WT 
70 25 4.97 WT WT 
71 50 5.15 DEL19 DEL15 
72 25 8 DEL19 DEL15 
73 40 60 WT WT 
74 30 20.8 WT WT 
75 50 0.5 WT WT 
76 10 5.4 WT WT 
 
Table 1. Idylla EGFR Mutation Assay performance on archival extracted DNA. 
A series of 76 archival DNAs extracted from lung adenocarcinoma cytological slides is reported. In all cases, the 
neoplastic cell percentage and the DNA concentration (ng/µL) were assessed. EGFR mutational status, 
previously tested by our laboratory reference method (fragment length and TaqMan assays), was re-evaluated by 
Idylla. 
DEL15, DEL18/21b/24, DEL9.21a: Idylla result reporting the different families of EGFR exon 19 deletions. 
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These latter smears had been wholly scraped, since featured a stochastic distribution 
of malignant and non malignant cells, which precluded tumour component enrichment by 
manual microdissection. Of these, 59 were Papanicolaou and 17 were Diff-Quik. Archived 
DNA was processed by the Idylla EGFR Prototype Mutation Test between November 2015 
and March 2016. As previously shown, we have directly pipetted 10 ng of extracted genomic 
DNA in the prototype EGFR cartridge. A total of 17/76 study cases featured either an air- 
dried Diff-Quik or a Papanicolaou stained cytological slide, in addition to slides that were 
previously used for DNA extraction. Any cytological slide was microscopically reviewed, 
annotating the neoplastic cell percentage and incubated in xylene for 3 days to allow 
coverslip removing. Each slide was dried and wholly scraped into an Idylla EGFR cartridge. 
 
Analysis of collected fluorescent signals 
 
Conversely to the Idylla BRAF and KRAS mutation tests, where Idylla™ console auto- 
analyses the PCR curve to determine the presence or absence of a mutation and the results 
are presented on screen as either ‘no mutation detected’ or ‘mutation detected’,1-3 the raw 
data obtained by the Idylla EGFR prototype on both DNA preparations and scraped cells 
were centrally analysed at Biocartis; this analysis was blind to the results previously obtained 
by our standard reference method. In principle, a cycle value (Cq) was calculated by Idylla 
beta version software for every PCR curve. The presence of a mutant genotype was 
determined by calculating the difference between the control and sample Cq (ΔCq). The 
mutant signal is considered valid if the ΔCq is within a validated range. All samples with a 
valid wild-type signal but a ΔCq value outside the validated range were characterised as 
EGFR mutation negative. Cases showing invalid results were further investigated to assess 
the reason behind the failure by evaluating DNA quality by a microfluidic platform based on 
electrophoretic system 4200 TapeStation (Agilent, Santa Clara, California, USA). 
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1.2.2 Results 
 
 
 
Idylla EGFR prototype sensitivity was evaluated on cell line-derived DNA. As reported 
in the methods section, we created dilutions down to 1% for both exon 19 and 21 EGFR 
mutations in wild-type DNA background. In any of the dilutions tested, the presence of EGFR 
mutant alleles was detected by the EGFR Idylla prototype. The Idylla™ results relative to the 
analysis of 76 cytology samples derived archival DNAs were compared with those obtained 
by our laboratory validated assays and reported in table 1 (figure 2). 
 
 
 
 
 
 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Discordance between standard reference method and Idylla™ relative to epidermal growth factor 
receptor exon 19. Case #40. (A) Fragment length electropherogram showing a clear wild-type allele peak and an 
additional very low peak of uncertain significance (B), Del15 mutation was detected by using the Idylla™ assay; 
note that two curves are detectable, one corresponding to wild-type allele and the other one to Del15-mutated 
allele. 
 
 
 
Briefly, Idylla™ yielded valid results in 74/76 (97.3%) samples in a first run. The two invalid 
samples, showing highly degraded DNA (figure 3), were excluded from the analysis. 
B 
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Figure 3. Archival DNA from a case showing epidermal growth factor receptor Idylla™ invalid result (#60) further 
investigated by a microfluidic platform based on electrophoretic system (4200 TapeStation, Agilent) to assess the 
reason behind the failure. Note that the electrophoretic profile features several peaks due to DNA fragmentation. 
 
 
 
All 32 mutant cases were confirmed by Idylla™, showing a sensitivity of 100%. In 
addition, in the group of 44 wild-type samples by our standard techniques, Idylla™ gave a 
discordant result in four cases. In particular, EGFR Idylla prototype revealed in cases 34 and 
40 an EGFR exon 19 deletion, whereas cases 32 and 62 featured a G719X exon 18 point 
mutation, not covered by our standard reference method. Only these two latter cases could 
be further investigated by Next Generation Sequencing (NGS), as cases 34 and 40 did not 
have sufficient residual DNA. In cases 32 and 62, the presence of G719A and G719C 
mutations was confirmed by NGS analysis. In 17/76 cases, an additional air-dried Diff-Quik 
stained cytological slide was available, and the EGFR Idylla prototype was carried out also by 
scraping cytological material directly in the cartridge. When the results were compared with 
those obtained on matched archival DNA, most of the cases (15/17) gave concordant results. 
Only two cases showed a discordancy, featuring an exon 19 deletion (case n. 15) and an 
L858R (case n. 25) point mutation detected only by EGFR Idylla prototype on archival DNA. 
Since Idylla™ system does, at the moment, not allow the withdrawal of extracted DNA from 
the cartridge, the discrepancies between archival DNA and directly scraped cytological 
material could not be further assessed. 
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1.2.3 Discussion 
 
 
 
Our data demonstrate that the Idylla EGFR Mutation Assay is a highly sensitive 
method that can consistently detect EGFR mutations with as little as 1% mutant DNA in a 
wild-type background, as shown in cell line studies. Thus, the Idylla EGFR Mutation Assay 
meets the CAP/IASLC/AMP guideline strong recommendation to use methodologies able to 
detect EGFR mutations in specimens with only 10% cancer cells.4 This requirement is 
particularly appropriate when testing cytological samples that often feature a stochastic 
distribution of malignant and non-malignant cells, which precludes tumour component 
enrichment by manual microdissection.9 In our series, the EGFR Idylla prototype showed a 
good performance, enabling in 100% of cases (32/32) the EGFR mutational status 
confirmation. In addition, this assay was able to resolve cases with low  intensity peaks on 
the fragment assay electropherograms of the uncertain technical interpretation but 
suggestive of clinical significance. In particular, cases n. 34 and 40, reported as negative by 
our reference methods were defined as mutant by EGFR Idylla prototype, as illustrated in 
figure 2, probably reflecting a higher sensitivity level. In addition, while these latter 
techniques cover only exon 19 deletions and L858R mutation, EGFR Idylla prototype has a 
broader reference range, as shown by cases 32 and 62, in which Idylla™ detected G719X 
exon 18 point mutations, also confirmed by our validated NGS approach. Noteworthy, the 
CAP/IASLC/AMP guideline strongly recommends to extend the EGFR mutational assessment 
also to exons 18 and 20 for the most common mutations4 and for lower prevalence variants, 
whose response to EGFR antagonists may differ.17 
Besides a high analytical sensitivity and a large reference range, the main advantage of the 
Idylla system is the possibility to extend the feasibility of EGFR testing to smaller 
laboratories, fully exploiting the automated workflow, which reduces the time required to 
genotype DNA for EGFR mutational status assessment in approximately 2.5 hours, 
compensating for the high cost of a single cartridge (∼ €200). Until recently, the automated 
Idylla tests for mutation detection in predictive molecular pathology were limited to 
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histological samples. This reflected the manufacturer design to process FFPE sections. We 
here showed that the Idylla EGFR prototype test was able to analyze also cytological 
samples, which is crucial since these specimens represent the most common available 
material to select patients for targeted treatments in clinical practice. In addition, we also 
showed that only 10 ng of archival DNA, directly pipetted into the cartridge, is sufficient to 
obtain results in most samples (74/76). Only two cases showing marked DNA degradation 
(figure 3) yielded an invalid result. 
The demonstration that Idylla™ reliably processes extracted DNA suits cytological practice, 
where often only a single slide is available. In this study, we also investigated the possibility 
to directly scrape cytological material from de-coverslipped archival smears into the 
cartridge; in fact, the sample preparation module of Idylla™ system uses high-frequency 
intensity focused ultrasound technology to enable automated DNA extraction. This enables 
performing mutation testing even without the basic expertise and equipment to perform 
DNA extraction and purification. While previous studies showed that a full concordance can 
be obtained between FFPE sections and extracted DNA, in this study, when scraping 
cytological material directly into the cartridge, cases 15 and 25 gave a false-negative result. 
Since in both cases the scraped material contained a tumour cell percentage sufficient for 
EGFR mutational status assessment (table 2), it is conceivable that the original cytological 
staining might have interfered with the detection of the fluorescence being developed 
during target amplification. 
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Case % Neoplastic Cells Idylla 
15 25 WT 
20 5 WT 
22 25 WT 
23 30 WT 
24 25 DEL 9/21a 
25 50 WT 
27 20 WT 
33 25 WT 
35 10 DEL 9/21a 
40 10 DEL 15 
41 40 WT 
42 20 WT 
43 50 WT 
44 5 WT 
45 5 WT 
46 25 WT 
47 15 WT 
 
Table 2. Idylla EGFR Mutation Assay performance on scraped cytological samples. 
A group of 17 study cases featured an archival cytological slide, in addition to slides previously used for DNA 
extraction. Any cytological slide was microscopically reviewed, annotating the neoplastic cell percentage and 
wholly scraped into an Idylla EGFR cartridge. 
 
 
 
Thus, further technological refinements are needed to better adapt the automated 
extraction modalities to stained cytological material. However, the possibility to use directly 
the extracted DNA may overcome the limitations in number of smears and abundance of 
material, inherent to cytological specimens. Furthermore, aliquoting of the extracted DNA 
may offer the opportunity to perform additional biomarker testing and to run an orthogonal 
technique for result confirmation. 
In conclusion, we showed that the fully automated molecular diagnostics system 
Idylla™ represents a promising option for EGFR mutation testing on cytological samples of 
lung cancer to enable taking, also in less experienced laboratories, very rapid treatment 
decisions with high sensitivity, large reference range and ease of use. 
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Chapter 2 
 
 
 
2.1 Idylla KRAS testing 
 
 
The Idylla™ KRAS mutation test is a single-use cartridge-based test designed for the 
qualitative detection of 21 KRAS mutations and including KRAS total (amplification region off 
the mutational hot-spot acting as sample processing control). Seven mutations are targeted 
in exon 2: p.G12C (c.34G>T), p.G12R (c.34G>C), p.G12S (c.34G>A), p.G12A (c.35G>C), p.G12D 
(c.35G>A), p.G12V (c.35G>T) and p.G13D (c.38G>A). Nine mutations can be detected in exon 
3: p.A59E (c.176C>A), p.A59G (c.176C>G), p.A59T (c.175G>A), p.Q61K (c.181C>A; 
c.180_181TC>AA), p.Q61 L (c.182A>T), p.Q61R (c.182A>G), and p.Q61H (c.183A>C; 
c.183A>T); whereas five mutations are targeted in exon 4: p.K117N (c.351A>C; c.351A>T), 
p.A146P (c.436G>C), p.A146T (c.436G>A), and p.A146V (c.437C>T). The assay has been 
designed by the manufacturer to process 5–10 μm formalin-fixed paraffin-embedded (FFPE) 
tissue sections or FFPE slices. The Idylla KRAS mutation test approved for in vitro diagnostic 
use by the European Community (CE-IVD) marked can genotype KRAS with 5% detection 
limit (LOD). The fully automated analysis required approximately 2 h. The Idylla™ console 
autoanalyzed the PCR curve to determine the presence or absence of a KRAS mutation and 
the results were presented on screen as either “no mutation detected” or “KRAS mutation 
detected”, indicating the specific mutation. 
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2.2 Idylla KRAS Mutation test on pancreatic aspirates 
 
 
 
Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) plays a crucial role in 
the management of pancreatic neoplastic lesions.18 More than 85% of pancreatic 
adenocarcinoma (PDAC) are diagnosed by EUS-FNA in an advanced stage when surgical 
pathological examination is precluded.19 As a general rule, EUS-FNA is a rapid, safe and cost- 
effective procedure.20 However, in up to 20% of cases, well-differentiated PDAC cannot 
reliably be distinguished from benign diseases such as chronic pancreatitis (CP) especially in 
its pseudo-tumoral form.20 In particular, EUS-FNA is less accurate, when PDAC is small, well 
vascularised or desmoplastic.21 Similarly, in patients with pancreatic cysts presenting for EUS 
evaluation, cyst fluid cytological examination has high specificity for malignancy but lacks 
sensitivity,22 not always being able to distinguish between benign cysts and premalignant or 
malignant mucinous cysts.5 
KRAS mutations represent an early genetic event in PDAC pathogenesis.23 Even if 
molecular biology cannot replace cytology, the presence of a KRAS mutation in an 
inconclusive EUS-FNA specimen taken from a solid lesion suggests malignancy, reducing the 
false-negative (FN) rate by 55.6%, according to a recent meta-analysis;24 conversely, the 
presence of wild-type KRAS may be evocative of benignity.24 –27 However, the presence of 
KRAS mutations is not entirely specific, occurring in a minority of patients with CP27 and in 
preinvasive dysplastic lesions.28 Since EUS-FNA smears often feature contaminating benign 
gastrointestinal cells, KRAS testing requires the use of a high analytically sensitive molecular 
technique. 
To date, real-time PCR (RT-PCR) assays have mostly been designed to target only 
exon 2 ‘hot-spot’ mutations25 29 Conversely, next-generation sequencing (NGS) ensures 
analytical sensitivity similar to that of mutation-specific assays, allowing for the detection of 
common and uncommon mutations, including those of KRAS exons 3 and 4.29 However, the 
NGS procedure requires a complex validation procedure,30 being cost-effective only in large 
volume centralised laboratories.31 The Idylla KRAS Mutation Test (Biocartis, Mechelen, 
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Belgium) recently received CE-IVD certification for the detection of 21 mutations in codons 
12 and 13 (exon 2), 59 and 61 (exon 3) and 117 and 146 (exon 4) of the KRAS gene, with a 
validated 5% limit of detection. This test, based on allele-specific RT-PCR and performed on 
the fully automated Idylla™ platform, provides sample to result functionality, enabling 
method standardization even in those diagnostic units without molecular expertise and 
infrastructure.1 3 The aim of this study was to validate this novel technology on 
indeterminate pancreatic EUS-FNA. 
 
 
 
2.2.1 Materials and Methods 
 
 
 
Selection of cases 
In this retrospective study, the clinical performance of the Idylla KRAS test was 
assessed on archival DNA from a well-characterized series of EUS-FNAs that had already 
been tested for KRAS mutational status in a prior study by using three different techniques 
—Sanger sequencing, Allele Specific Locked Nucleic Acid PCR (ASLNAqPCR) and 454 Next 
Generation Sequencing (454-NGS)—as previously reported.29 Details regarding the modality 
of EUS-FNA sample collection and specimen handling and preparation for microscopic 
observation have been described.29 Briefly, in any single case an aliquot of the aspirated 
material, besides microscopic slide preparation, had directly been collected in a tube 
containing 100% ethanol for KRAS analysis (‘direct’ EUS-FNA material). Specimens were 
stored at room temperature for a period of up to two weeks and, then, DNA was extracted, 
as previously described.29 The criterion for including samples in this study, aiming to assess 
Idylla KRAS test performance, was the availability of at least 20 mL of archival DNA. Overall,  
a total of 52 cases were selected to undergo Idylla KRAS test. Results were compared with 
those previously obtained by Sanger sequencing, ASLNAqPCR and 454-NGS. Archived cases 
were processed with Idylla KRAS Mutation Test between October and December 2015. 
The assay has been designed by the manufacturer to process 5–10 μm formalin-fixed 
paraffin-embedded (FFPE) tissue sections or FFPE slices. However, for other applications 
disposable cartridges have been applied to liquid sample types, including swab, blood, urine, 
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stool, sputum and tissue.32 To perform the analysis on the archival EUS-FNA DNA, 3 µL 
(corresponding to 1/10th of a DNA preparation from the aspirate sample) of extracted 
genomic DNA was directly pipetted inside an Idylla KRAS Mutation Test cartridge. The 
cartridge was loaded onto the Idylla™ system for processing. Via microfluidic channels in the 
cartridge, nucleic acids are transported into five separate PCR chambers, which contain pre- 
deposited PCR reagents in dried form (i.e., primers, probes, enzymes) for the analysis of the 
sample DNA that includes KRAS Total (wild-type gene acting as Sample Processing Control). 
Detection of these specific targets is performed using fluorescently labelled probes. The 
Idylla™ console auto-analyses the PCR curve to determine the presence or absence of a KRAS 
mutation and the results are presented on screen as either ‘no mutation detected’ or ‘KRAS 
mutation detected’.33 A quantification cycle value (Cq) value is calculated by Idylla™  
software for every valid PCR curve. The presence of a mutant genotype is determined by 
calculating the ΔCq, that is, the difference between the KRAS wild-type Cq and the cut-offs 
for individual mutations. Mutant signal is considered valid if the ΔCq is within a validated 
range, and the sample will then be characterised as KRAS mutation positive, indicating the 
specific mutation. Noteworthy, the Idylla KRAS Mutation Test does not report double 
mutants, and in these cases, only the mutation with smallest ΔCq is called. All samples with a 
valid wild-type signal but a ΔCq value outside the validated range are characterized as ‘no 
mutation detected’. 
 
Statistical measures of clinical performance 
 
Idylla™ clinical performance was evaluated according to the final end point. This was 
represented by cytological, histological or, in cases of inoperable neoplasms, by clinical 
features. On this basis, we distinguished three different categories of lesions: (i) benign 
lesions, including non-neoplastic or benign cysts and a pancreatitis; (ii) adenocarcinomatous 
lesions or precursor lesions of adenocarcinoma, including PDAC, intraductal papillary 
mucinous neoplasms (IPMNs) and inoperable neoplasias with overt malignant clinical 
features; (iii) not adenocarcinomatous lesions, including pancreatic neuroendocrine tumour 
(pNET) and solid pseudopapillary tumours (SPPTs). Idylla clinical performance was assessed 
by evaluating its clinical sensitivity, specificity, negative predictive value (NPV), positive 
predictive value and accuracy also in comparison to Sanger sequencing, ASLNAqPCR and 
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454-NGS performance. True positives were cases that showed a mutation in KRAS and that 
were PDAC, inoperable neoplasias or IPMNs according to final end point. False positives 
were cases in which a mutation was found but with a ‘benign’ end point or else diagnosed as 
SPPT or pNET. True negatives were cases with a wild-type KRAS result and a ‘benign’ end 
point or with an end point of neuroendocrine or pseudopapillary neoplasia. FNs were cases 
with a wild-type KRAS but were PDAC/inoperable neoplasias or IPMN at the final end point. 
Comparisons between clinical sensitivities were performed according to recommendations 
previously described. 
 
 
 
2.2.2 Results 
 
 
 
A total of 52 archival DNA from EUS-FNA pancreatic samples was tested at the 
University of Naples Federico II with the Idylla KRAS Mutation Test. Representative examples 
of PCR curves and the corresponding Cq values for different Idylla™ analysis results are 
shown in figure 4. 
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Figure 4. Example of concordant molecular results in a KRAS exon 2 mutated sample. 
(A) Electropherogram obtained using Sanger sequencing. The KRAS-G12V mutation (c.35G>T) is pointed by an 
arrow. (B) KRAS-G12V mutation was also detected using Allele Specific Locked Nucleic Acid PCR assay: two 
curves are detectable, one corresponding to wild-type allele and the other one to G12V-mutated allele. (C) Profile 
obtained using 454-Next Generation Sequencing. The KRAS-G12V mutation is identified by the vertical red bar. 
The percentage of mutated alleles is indicated on the left y-axis while the total number of reads on the right one. 
(D) Representative examples of Idylla™ analysis result showing a KRAS-G12V mutation detection call. 
 
 
 
 
 
The results were compared with the original assessments made by Sanger sequencing, 
ASLNAqPCR and 454-NGS at the University of Bologna (table 3). 
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N° 
Cytological 
diagnosis 
Final diagnosis 
(Cytology+hystology) 
 
Age 
 
Gender 
 
454-NGS 
 
% 
 
ASLNAq PCR 
 
SANGER 
 
IDYLLA 
1 C5 PDAC 54 M WT  WT WT WT 
2 C5 PDAC 84 M G12R 22.0 G12R G12R G12R 
3 C5 Inoperable neoplasm 54 F WT  WT WT WT 
4 C5 PDAC 76 F G12D/G12V 28.5 / 1 G12D/G12V G12D G12D 
5 C5 PDAC 76 M G12D/G12V 21 / 15 G12D/G12V G12D/G12V G12V 
6 C5 PDAC 75 M G12V/Q61H 19.2 / 11.3 G12V G12V Q61H 
7 C5 pNET 66 M WT  WT WT WT 
8 C5 PDAC 61 M G12D 19.3 G12D WT G12D 
9 C5 PDAC 47 F Q61H 15.0 WT WT Q61H 
10 NA IPMN 68 F G12V 1.0 G12V WT WT 
11 C5 PDAC 58 M G12V 32 G12V G12V G12V 
12 C5 Inoperable neoplasm 71 M G12V 21.2 G12V G12V G12V 
13 C5 Inoperable neoplasm 62 M G12D 3.0 G12D WT G12D 
14 C5 pNET 79 M WT  WT WT WT 
15 C5 pNET 58 F WT  WT WT WT 
16 C5 pNET 46 F WT  WT WT WT 
17 C5 pNET 61 M WT  WT WT WT 
18 C4 PDAC 68 F WT  WT WT WT 
19 C1c IPMN 63 F Q61R 1.1 WT WT WT 
20 C5 PDAC 75 F G12V 3.7 G12V WT G12V 
21 C1c Benign cyst 46 F WT  WT WT WT 
22 NA IPMN 60 F Q61H 1.4 WT WT WT 
23 NA NA 64 F G12C/G12V 2.6 / 2 G12C/G12V WT G12C 
24 C1c NA 72 F G12V 27 G12V G12V G12V 
25 C2 Pancreatitis 43 M WT  WT WT WT 
26 C1c IPMN 71 M G12V 20.0 G12V G12V G12V 
27 C1c IPMN 71 M Q61H 4.3 WT WT WT 
28 C1c Benign cyst 80 M WT  WT WT WT 
29 C1c Benign cyst 81 F WT  WT WT WT 
30 C1c Benign cyst 49 F WT  WT WT WT 
31 C1c Benign cyst 64 F WT  WT WT WT 
32 C1s Inoperable neoplasm 84 F WT  WT WT WT 
33 C1c IPMN 73 M Q61H 2.0 WT Q61H Q61H 
34 C1c IPMN 76 M G12V 23.0 G12V G12V G12V 
35 C3 Inoperable neoplasm 78 F G12R 23.0 G12R G12R G12R 
36 C1c NA 75 F G12V 2.7 G12V WT WT 
37 C2 Benign cyst 73 M WT  WT WT WT 
38 C2 Benign cyst 53 M WT  WT WT WT 
39 C2 Benign cyst 73 F WT  WT WT WT 
40 C5 SPPT 47 F WT  WT WT WT 
41 C5 SPPT 17 M WT  WT WT WT 
42 C4 PDAC 78 F Q61L 32.0 WT Q61L Q61R/L 
43 C4 PDAC 69 F WT  WT WT WT 
44 C4 Inoperable neoplasm 66 F G12D 33.9 G12D G12D WT 
45 C4 PDAC 72 M G12D 4.1 G12D WT WT 
46 C1c IPMN 72 F WT  WT WT WT 
47 NA NA 41 F WT  WT WT WT 
48 C4 PDAC 67 F G12R 12.0 G12R WT G12R 
49 C3 PDAC 50 F WT  WT WT WT 
 
Table 3. Series of 49 endoscopic ultrasound-guided fine-needle aspiration tested for KRAS mutational status by 
using four different techniques: Allele Specific Locked Nucleic Acid PCR, 454 Next Generation Sequencing (454- 
NGS), Sanger sequencing and Idylla KRAS test. % indicates percentage of mutant allele by 454-NGS. Cytological 
evaluation is reported as unsatisfactory (C1), negative for malignancy (C2), atypical cells present (C3), suspicious 
for malignancy (C4) or positive for malignancy (C5), (NA) not available. 
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Idylla™ yielded valid results in 47/52 samples in a first run. The five invalid samples 
underwent a second run by increasing the DNA input up to 6 µL. Two cases gave a valid call, 
for a total of 49/52 (94.2%) adequate Idylla KRAS Mutation tests. KRAS mutation detection 
by four different techniques according to preoperative cytology evaluation and 
clinicopathological end points is reported in table 4. 
 
 
 
Cytology 
diagnosis 
(number of 
cases) 
 
454-NGS 
 
End point 
of mutated 
samples 
 
ASLNAqPCR 
 
End point 
of mutated 
samples 
 
Sanger 
 
End point 
of mutated 
samples 
 
Idylla 
 
End point 
of mutated 
samples 
C1 (14) 7 (50%) 5 IPMN 
2 NA 
4 (28%) 2 IPMN 
2 NA 
4 (28%) 3 IPMN 
1 NA 
4 (28%) 3 IPMN 
1 NA 
C2(4) 0  0  0  0  
 
C3(2) 
 
1(50%) 
Inoperable 
neoplasms 
 
1(50%) 
Inoperable 
neoplasms 
 
1(50%) 
Inoperable 
neoplasms 
 
1(50%) 
Inoperable 
neoplasms 
C4(6) 4(67%) 3 PDAC 
1 inoperable 
neoplasm 
3(50%) 2 PDAC 
1 inoperable 
neoplasm 
2(33%) 1 PDAC 
1 inoperable 
neoplasm 
2(33%) 2 PDAC 
 
C5 (19) 
 
10 (52%) 
 
8 PDAC 
2 inoperable 
neoplasms 
 
9 (47%) 
 
7 PDAC 
2 inoperable 
neoplasms 
 
6 (31%) 
 
5 PDAC 
1 inoperable 
neoplasm 
10 
(52%) 
 
8 PDAC 
2 inoperable 
neoplasms 
NA (4) 
 
Total (60) 
3 (75%) 2 IPMN 
1 NA 
2 (30%) 1 IPMN 
1 NA 
0  1 (25%) 1 NA 
 
Table 4. KRAS mutation detection by four different techniques according to preoperative cytology evaluation 
and clinicopathological endpoints. Cytological evaluation is reported as unsatisfactory (C1), negative for 
malignancy (C2), atypical cells present (C3), suspicious for malignancy (C4) or positive for malignancy (C5), 
(NA) not available. 
 
 
 
 
Briefly, KRAS mutations were found by Idylla™ in the 4/14 (28.6%) of inadequate 
samples (C1), in one of the two cases (50.0%) with atypical cells (C3), in 2/6 (33.3%) of the 
cases suspect for malignant neoplasia (C4) and in the 10/19 (52.6%) of samples diagnosed as 
malignant (C5). None of the benign (C2) cases showed KRAS gene mutations, and they were 
benign cysts (three cases) or pancreatitis (one case) on follow-up. One of four cases without 
available material for cytological evaluation was mutated for KRAS by Idylla KRAS Mutation 
Test. Considering the final end point information available in 45 cases, we detected a KRAS 
mutation in 16/29 (55.2%) adenocarcinomatous and pre-neoplastic lesions (in 10/15 of 
PDAC, 3/8 of IPMNs and in the 3/6 of inoperable neoplasms), while no KRAS mutations were 
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observed in not adenocarcinomatous or in benign lesions. In 15/49 (30.6%) cases, discordant 
results in KRAS mutational status were obtained using at least one of the four different 
techniques, as reported in table 3. 
 
Discordant KRAS results in relation to mutant allele abundance 
 
To evaluate the reason for discordant results among different techniques (15/49), the 
rate of mutant allele (MA) yielded by 454-NGS was taken into account when evaluating 
methods performance. In five discordant cases (#8, #9, #19, #42, #44 and #48) the MA 
abundance, as detected by 454-NGS was >10%. In cases #8 (MA=19%) and #48 (MA=12%), 
KRAS exon 2 gene mutations were missed by Sanger sequencing. Cases #9 (MA=15%) and 
#42 (MA=32%) harboured a mutation in KRAS exon 3, which was undetectable by 
ASLNAqPCR and missed in one instance (case #9) by Sanger sequencing. In case #44 
(MA=34%), KRAS G12D mutation was missed by Idylla KRAS Mutation Test. In 10 discordant 
cases (#10, #13, #19, #20, #22, #23, #27, #33, #36 and #45), <5% of MA was identified by 
454-NGS. A representative example of discordant results (case #19) is shown in figure 5. 
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Figure 5. Example of discordant molecular results in a KRAS exon 3 mutated sample. 
(A) Electropherogram obtained using Sanger sequencing, showing a native nucleotide sequence. Codon 61 is 
marked by two pink vertical bars. (B) No KRAS mutation (codons 12–13) was detected using Allele Specific 
Locked Nucleic Acid PCR assay: only the curve corresponding to the wild-type allele is visible. (C) Profile 
obtained using 454-Next Generation Sequencing. The KRAS-Q61R mutation is identified by the vertical black bar. 
The percentage of mutated alleles is indicated on the left y-axis while the total number of reads on the right one. 
(D) The KRAS-Q61R mutation was not detected by Idylla. 
 
 
 
 
 
Only case #33 was detected by Sanger sequencing, whereas ASLNAqPCR confirmed 
454-NGS results, not considering cases #19, #22, #27 and #33 harbouring an exon 3 KRAS 
mutation that was undetectable by this technique. Also, 4 of 10 low-abundant discordant 
cases were detected by Idylla™. In particular, in four cases that showed between 3% and 5% 
of MA (#13, #20, #27 and #45), two mutant cases (#13 and #45) were detected by Idylla 
KRAS Mutation Test. Out of two cases that showed between 2% and 3% of MA (#23 and 
#36), one mutant case (#23) was detected by Idylla KRAS Mutation Test. Among four cases 
that showed <2% of MA (#10, #19, #22 and #33), only one case (#33) was detected by Idylla 
KRAS Mutation Test. Statistical measures of performance Idylla KRAS Mutation Test had 
100% specificity, a clinical sensitivity (55.1%) higher than Sanger sequencing (41.3%), and 
identical to that of ASLNAqPCR (55.1%). Clinical sensitivity (71.1%), NPV (69.6% vs 55.1%) 
and accuracy (82.546% vs 71.1%) of 454-NGS were higher than Idylla KRAS Mutation Test. 
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When the cases with <5% MA were excluded from the analysis, the Idylla KRAS Mutation 
Test clinical sensitivity increased up to 61.9% (with 100% specificity), higher than Sanger 
sequencing (52.3%) and ASLNAqPCR (57.1%). Clinical sensitivity (66.6% vs 61.9%), NPV 
(69.6% vs 66.6%) and accuracy (81.1% vs 78.3%) of 454-NGS were similar to Idylla KRAS 
Mutation Test. 
 
 
 
 
2.2.3 Discussion 
 
 
 
In both cystic and solid pancreatic lesions, the assessment of KRAS mutational status 
may be useful to refine the diagnosis of uncertain EUS-FNA samples;21 while in solid lesions, 
to state malignancy is crucial, in cystic lesions, the approach is different and is nowadays 
more to differentiating mucinous from non-mucinous lesions. In any case, KRAS testing 
should have a fast turnaround testing, in line with the need of urgent clinical actions. Thus, 
instead of outsourcing suspicious pancreatic EUS-FNA to a small number of referral 
molecular pathology laboratories, KRAS testing may be carried out in the same centre where 
the patient is being diagnosed, enabling the most cellular slide to be easily selected from in- 
house collected cytological material. However, KRAS testing is difficult to be implemented in 
cytopathology laboratories, with little expertise in molecular biology procedures and in- 
house validation of a laboratory-developed methods. 
The Idylla KRAS Mutation Test, a rapid and fully automated CE-IVD (European 
Conformity-In Vitro Diagnostic)-certified test, can represent a valid option for a wider 
number of pathological centres.1-3 The assay has been designed by the manufacturer to 
process FFPE tissue sections using high-frequency intensity-focused ultrasound technology 
to obtain amplifiable DNA.1-3 In this study, however, we have shown that the extracted DNA 
can directly be placed inside an Idylla KRAS Mutation Test cartridge. Usually the EUS-FNA 
sampling of a pancreatic lesion yields abundant contaminating gastrointestinal cells; thus, a 
highly analytical sensitive technique is required to detect KRAS mutation in a minority of 
neoplastic cells.34 On the other side, a supersensitive test may detect early KRAS mutant 
clones even in small foci of pancreatic intraepithelial neoplasia, whose clinical significance is 
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questionable.35 As stated by the manufacturer, the Idylla KRAS Mutation Test has a limit of 
detection of 5% (validated at the 95% CI) of MA, which seems to be well suited for clinical 
applications. Accordingly, in this study, the Idylla KRAS Mutation Test had a clinical sensitivity 
(55.1%) higher than Sanger sequencing (41.3%), but lower than 454-NGS (71.1%).In fact, 
454-NGS had the capability to detect small mutant clones in 10 cases, which was achieved in 
only four cases by Idylla™. Noteworthy, low abundance mutant cases usually were IPMN; 
only case #55, featuring as little as 4% of MA and detected only by 454 NGS was an overt 
malignant neoplasm. When the low-abundant mutant cases were excluded from the 
analysis, the Idylla KRAS Mutation Test clinical sensitivity increased from 55.1% up to 61.9% 
approaching that of 454-NGS (66.6%). The allelic discrimination laboratory-developed 
technique can be applied to EUS-FNA with several advantages as it was very recently shown 
by Bournet et al,25 who developed TaqMan probe sets to identify the most prevalent KRAS 
codon 12 mutations(p.G12R- c.34G>C; p.G12D- c.35G>A; p.G12V-c.35G>T). In their 
experience, based on the analysis of solid suspect pancreatic lesions, the sensitivity of 
cytopathology alone increased from 73% to 88%25 Compared with a similar qRT-PCR-based 
approach, ASLNAqPCR, Idylla KRAS Mutation Test was less sensitive in low-abundant MA 
cases, but detected exon 3 mutations in four instances. Only one of these cases harbouring a 
double G12V/Q61H mutation was detected by ASLNAqPCR. No mutation were detected in 
exon 4, confirming that these are uncommon in pancreatic cancer.29 Their inclusion in the 
reference range of the Idylla KRAS Mutation Test probably reflects its design for other 
common cancer types, such as colon cancer. Overall, six different mutation types (G12C, 
G12D, G12R, G12V, Q61H and Q61R/L) were detected by the Idylla KRAS Mutation Test, 
confirming that the whole spectrum of clinically relevant mutations for pancreatic cancer is 
covered.21 The clinical specificity of Idylla KRAS Mutation Test was 100% and no  mutant 
cases were detected in benign lesions; conversely, Idylla KRAS Mutation Test missed only 
one G12D mutation detected by ASLNAqPCR and confirmed by Sanger sequencing. It may be 
important to note that the Idylla tests were performed on archived DNA that had been 
stored for several years and shipped to Naples before testing, while the other methods used 
freshly prepared DNA tested directly in Bologna. To assess whether a confirmation may be 
needed to avoid any possibility of FN results, a prospective study is required. Additionally, 
the performance of the Idylla KRAS Mutation test may be further improved by prior 
cytological observation of the harvested material and tumour cell enrichment.29 In 
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conclusion, this is the first study that applied the novel Idylla KRAS test to the clinical setting. 
In particular, this system can be easily implemented in the routine assessment of pancreatic 
EUS-FNA samples to quickly provide information on KRAS mutational status that can 
supplement cytological evaluation. 
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2.3 Idylla KRAS testing on archival cytological smears 
 
 
 
Subsequently to the previous experience with Idylla KRAS testing on extracted DNA 
from fresh cells of pancreatic EUS-FNA, it was evaluated this assay performance on the DNA 
extracted from archival smears of pancreatic lesions and metastatic CRC. In routine practice, 
KRAS testing is usually performed on resected primary tumor samples of CRC, but the 
cytological sampling of the metastatic sites is useful when there is complete response to 
neoadjuvant in patients with rectal cancer6 and to serially monitor for the emergence of 
mutant treatment resistant clones.7 8 
In both pancreatic and colorectal cancer patients, KRAS testing should have a fast 
turnaround testing, in line with the need of urgent clinical actions. Thus, instead of 
outsourcing cytological samples to a small number of referral molecular pathology 
laboratories, KRAS testing may be carried out in the same center where the patient is 
diagnosed. Unfortunately, the competence needed to validate and run complex molecular 
diagnostic assays is beyond most cytopathology laboratories.10 However, the automated 
allele-specific real-time polymerase chain reaction (RT-PCR) technology is advancing at rapid 
pace. In particular, the fully automated molecular diagnostics system Idylla™ is a fascinating 
technology.1-3 Sample preparation is combined with PCR thermocycling and fluorescence 
detection of target sequences. Without needing highly skilled staff, within approximately 90 
min, the Idylla™ mutational tests approved for in vitro diagnostic use by the European 
Community (CE-IVD) marked can genotype KRAS with 5% detection limit, enabling method 
standardization even in those diagnostic units without molecular infrastructures.14 Although 
the Idylla™ tests were designed for use with formalin-fixed paraffin-embedded (FFPE) 
sections, as we previously have shown the Idylla™ system can also process DNA preparations 
obtained from fresh cells.14 The aim of this study is to assess Idylla™ performance on the 
DNA extracted from archivial smears of pancreatic and mCRC. 
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2.3.1 Materials and Methods 
 
 
Study cases 
 
The database of the Cytopathology Department at the University of Naples was 
searched to select archival smears of pancreatic cancer (n = 10) and metastatic 
adenocarcinoma of colorectal origin (n = 11). The smears were reviewed by two qualified 
pathologists, EV and MdA, and the diagnosis was confirmed, and in all cases, the purity of 
tumor cells was estimated as a percentage of malignant cells out of the total nucleated cells. 
Since the analytic sensitivity of the Idylla™ test is high (5% of mutant allele detection), cases 
were selected without a specific requirement of neoplastic cellularity. Archival smears were 
processed between March and May 2016. A single slide was retrieved for each case. Each 
slide was incubated in xylene for 3 days to allow coverslip removing and air-dried; tumor 
cells were scraped off directly from the whole glass surface. Genomic DNA was extracted 
using the QIAamp DNA Mini Kit (Qiagen, Crawley, West Sussex, UK) and quantified (ng/μl) as 
previously described.36 All cases were tested by Idylla™ regardless from the DNA 
concentration. Since KRAS mutational analysis is part of the routine diagnostic workup of 
patients with pancreatic and colorectal lesions, the need for Ethic Committee’s approval was 
not necessary for this study, in accordance with Medical Ethical Guidelines of the University 
Federico II Medical School. Accordingly to these guidelines, a comprehensive written 
informed consent was signed for the procedure (fine needle aspiration) that produced the 
tissue samples. All information regarding the human material was managed using 
anonymous numerical codes. All samples were handled in compliance with the Declaration 
of Helsinki (http://www.wma.net/ en/30publications/10policies/b3/). 
To perform the analysis, 10 ng of extracted genomic DNA was directly pipetted inside 
an Idylla KRAS mutation test cartridge. This latter was, then, loaded into the Idylla™ 
instrument. The fully automated analysis required approximately 2 h. The Idylla™ console 
autoanalyzed the PCR curve to determine the presence or absence of a KRAS mutation and 
the results were presented on screen as either “no mutation detected” or “KRAS mutation 
detected,” indicating the specific mutation. To assess the performance of Idylla KRAS 
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mutation test, in any single case, extracted DNA was analyzed by the CE-IVD marked Easy 
KRAS kit (Diatech Pharmacogenetics, Jesi, Italy) on a QuantStudio 5 instrument (Thermo 
Fisher, Monza, Italy) and the obtained results were compared.37 The CE-IVD marked Easy 
KRAS kit detects all relevant mutations of exon 2, 3, and 4 of KRAS by standard RT-PCR. 
 
 
 
2.3.2 Results 
 
 
Idylla™ yielded valid results in 18/21 (85.7%) samples (Table 5) in a first run. 
 
 
 
N. 
CASE 
 
SITE 
CYTOLOGICAL 
DIAGNOSIS 
SMEAR 
STAINING 
% NEOPLASTIC 
CELLS 
[ng/µl] REAL-TIME PCR 
 
IDYLLA 
1 Pancreatic body PDAC PAP 15 0,7 WT WT 
2 Pancreatic head PDAC PAP 5 3,62 WT WT 
3 Pancreatic body PDAC PAP 15 2,74 WT WT 
4 Pancreatic head PDAC PAP 60 3,59 WT WT 
5 Pancreatic head PDAC PAP 15 2,86 WT WT 
6 Pancreatic head-body PDAC DIFF QUIK 25 9,43 MT (G12D) MT (G12D) 
7 Pancreatic head-body PDAC PAP 40 2,61 MT (Q61X) MT (Q61H) 
8 Pancreatic head PDAC DIFF QUIK 50 3,57 MT (G12R) MT (G12R) 
9 Pancreatic head PDAC PAP 50 >60 MT (G12V) MT (G12V) 
10 Lung mCRC PAP 35 1,02 WT WT 
11 Abdominal wall mCRC DIFF QUIK 15 0,1 WT WT 
12 Peritoneal effusion mCRC PAP 35 2,49 MT (G12D) MT(G12D) 
13 Liver mCRC DIFF QUIK 45 40,7 MT (A59X) MT(A59E/G/T) 
14 Abdominal wall mCRC DIFF QUIK 30 >60 MT (G12D) MT(G12D) 
15 Lung mCRC PAP 50 7,97 MT (G12D) MT(G12D) 
16 Abdominal wall mCRC DIFF QUIK 50 1,6 MT (G13D) MT(G13D) 
17 Abdominal wall mCRC DIFF QUIK 60 2,74 MT (A59X) MT(A59E/G/T) 
18 Lung mCRC PAP 40 5,46 MT (G12V) MT(G12V) 
 
Table 5. Idylla KRAS performance on DNA extracted from 18 archival smears. 
For any case the specimen site, the cytological diagnosis and staining, the neoplastic cell percentage and the 
DNA concentration (ng/μl) are shown KRAS mutational status was tested by Idylla™ and results were 
compared to standard RT-PCR. 
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Three samples, whose DNA concentration was <0.5 ng/μl, gave an invalid result. Only 
one of these cases was successfully amplified by the Easy KRAS kit, resulting wild type (WT). 
On the overall, the group of 18 cases, was equally composed (n = 9) by pancreatic and mCRC 
smears. Papanicolaou-stained smears were more frequent (n = 11) than Diff-Quik-stained 
smears (n = 7). A total of 11 cases showed a KRAS mutation, and a representative example is 
reported in Figure 6. 
 
 
 
 
 
 
 
 
 
Figure 6. Example of concordant molecular results in a KRAS exon 2 mutated sample. (case #8, Table 
5). Archival DNA was extracted from a Diff-Quik-stained smear of pancreatic cancer featuring 50% of 
neoplastic cells and a concentration of 3,57 ng/μl. Representative graphs of standard real-time 
polymerase chain reaction and Idylla™ are reported both showing G12R KRAS mutation. 
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In all cases, the Easy KRAS kit confirmed the obtained results (Table 5). In particular, 
the mutations detected by both techniques were the following: p.G12D (n = 4), p.G12V (n = 
2), p.G12R (n = 1), p.G13D (n = 1), p.A59E/G/T (n = 2), p.Q61H (n = 1). Four mutant cases 
(p.G12D, p.G12R, p.G12V, and p.Q61H) were observed in the group of pancreatic smears, 
whereas seven mCRC smears harbored a KRAS mutation (n = 3 p.G12D; n = 2 p.A59E/G/T; n = 
1 p.G12V; n = 1 p.G13D). The absence of mutations in five pancreatic and two mCRC smears 
was also confirmed by Easy KRAS kit. Noteworthy, most of the wild-type pancreatic cancer 
featured a low cellularity with the presence of <20% of cancer cells. 
 
 
 
 
 
2.3.3 Discussion 
 
 
 
On pancreatic fresh cells, collected by fine-needle aspiration and directly immersed in 
a tube with a preserving buffer, Idylla KRAS test showed a clinical sensitivity higher than 
Sanger sequencing.14 Similar to that observed on pancreatic fresh cells, also on archival 
smears, the Idylla KRAS test performance is high and similar to that of Easy KRAS kit. In fact, 
the two methods showed a complete concordance, alleviating the concern of possible false 
negative results by Idylla™. According to manufacturer, the minimum tumor percentage to 
avoid false negative results is 10%. Thus, there was only onecase (#2) with really low tumor 
(5%) that does not rule out the possibility of false negative results by Idylla™. However, 
recent cell line dilution data showed that the EGFR L858R point mutation can be detected by 
Idylla™ even at 1% dilution.38 
Noteworthy, the rate of wild-type pancreatic adenocarcinoma was higher than the 
documented rates in most other published series.34 This may reflect the limited number of 
cases tested but may also be explained by the low (<20%) neoplastic cellular content of most 
(4/5) cases. In addition, due to the stochastic distribution of benign and malignant cells, in 
these cases, manual microdissection to enrich for neoplastic cells was unfeasible, leading to 
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a further dilution of potentially present mutant alleles. These limitations may be overcome 
by the more sensitive next-generation sequencing,29 whose implementation is cost-effective 
only in large volume centralized laboratories.31 Conversely, we showed that Idylla™ may be 
easily adopted by a large number of cytopathology laboratories. 
Only three cases yielded an invalid result that was likely due to insufficient DNA (<0.5 ng/μl). 
Although this system has obtained the CE-IVD mark for FFPE material, the extracted DNA 
from routine smears can be directly pipetted into the cartridge, which may be automatically 
run as if an FFPE sample had been inserted. This off-label use of the Idylla™ test should not 
be seen as limiting factor since it is the same use of direct smears that classifies the 
procedure as a laboratory developed test, requiring in-house validation and quality control 
monitoring. 
The time required to genotype DNA for KRAS mutational status assessment is approximately 
2 h, compensating for the high cost related to the CE-IVD mark of a single cartridge (∼€150). 
Although the process of removing the coverslip of archival smears does not compromise the 
quality of the DNA, it is time-consuming. In this study, smears archived for at least 2 years 
were employed, requiring even 3 days, but to avoid any delay, rapid on-site evaluation, at 
the time of the FNA procedure, enables the best triage of the sample for diagnosis and 
ancillary studies and the selection of a representative slide, that it is maintained 
uncoverslipped for immediate DNA extraction and Idylla™ processing.34 
Our results, showing that mCRC smears can reliably be tested by Idylla for KRAS mutation, 
and the recent availability of Idylla NRAS/BRAF test can give the cytopathologist the 
opportunity to sample metastatic sites to perform molecular analysis on cytological smears 
when histological resections are not available or when the patient is monitored to early 
detect the arising of mutant-resistant clones.7 
In conclusion, this study demonstrates that the fully automated molecular diagnostics 
system Idylla™ is a promising opportunity for KRAS mutation testing on cytological samples. 
Even in less experienced laboratories, the cytopathologist may easily integrate 
morphological diagnostic report with accurate molecular information relevant for diagnostic 
and treatment decisions. However, it should be born in mind that long-term experiences are 
required to assess the feasibility of this automated molecular diagnostics system, and 
specific educational programs are required to enable pathologists to review and sign out 
clinical molecular genetic/molecular pathology results, and meanwhile, the relevance of a 
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staff board-certified molecular pathologist or clinical molecular geneticist cannot be 
overemphasized. 
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